MDLinxBeyond First-Line Failure: Rethinking Care in Refractory mSCLC

Second-line therapy in platinum-refractory or early-relapsing metastatic small-cell lung cancer is routinely underestimated, but experts argue it warrants reconsideration. For patients with adequate performance status, treatment can provide disease control, symptom palliation, and access to clinical trials even when response rates are modest.

Clinical Considerations

• Platinum-refractory mSCLC carries a nihilistic bias among clinicians and patients, but second-line therapy can slow progression and preserve functional status
• Alkylating agents show survival benefit with tolerability advantages over other second-line options
• Topoisomerase I inhibitors, platinum rechallenge, and multi-agent chemotherapy remain active second-line strategies
• Second-line treatment may preserve eligibility for clinical trials, critical given the active novel agent pipeline in SCLC

Practice Applications

• Reassess second-line candidacy in platinum-refractory mSCLC patients with adequate performance status
• Discuss realistic goals with patients: disease control and symptom management, not cure
• Prioritize clinical trial enrollment as a second-line pathway where available
• Individualize agent selection based on tolerability profile and patient goals

More in SCLC